AuthorsLeeson, Simon C
Redman, Charles W E
Rieck, Gudrun C
Petry, K Ulrich
Affiliation1Department of Obstetrics and Gynaecology, Betsi Cadwaladr University Health Board, Bangor, Gwynedd, UK; 2Department of Gynecology, National Screening Center, Tbilisi, Georgia; 3Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium; 4Laboratoire Cerba, Paris, France; 5Department of Gynecology and Obstetrics, University of Bari, Bari, Italy; 6Hôpital Tenon, Service de Gynécologie Obstétrique et Médecine de la Reproduction, Paris, France; 7Department of Obstetrics and Gynecology, Helsinki University Hospital, Finland; 8The Beacon Hospital, Sandyford, Dublin, Ireland; 9Department of Obstetrics and Gynaecology, University Hospital of North Staffordshire, Stoke-on-Trent, UK; 10D-18437 Stralsund, Grünthal, Germany; and 11Department of Obstetrics and Gynaecology, Klinikum Wolfsburg, Wolfsburg, Germany.
MeSHCervical Intraepithelial Neoplasia
Early Detection of Cancer
Uterine Cervical Neoplasms
MetadataShow full item record
CitationLeeson, S.C. et al., 2014. The future role for colposcopy in Europe. Journal of Lower Genital Tract Disease, 18 (1), pp 70-8
JournalJournal of lower genital tract disease
AbstractImprovements in the performance of cervical screening may be limited by the diagnostic performance of colposcopy. Nonetheless, colposcopy remains the best available tool to assess women considered at high risk for having or developing cervical cancer. The provision and role of colposcopy across Europe is variable. Introduction of vaccination against human papillomavirus (HPV) types 16 and 18 as well as the possible switch to HPV-based screening is likely to change the profiles of women presenting to colposcopy services and provide management difficulties for the colposcopist.The standard of colposcopy in Europe can be maintained or improved despite a variable availability of screening. The prevalence of cervical intraepithelial neoplasia grade 3 may decrease for women having had HPV vaccination. The incidence of cervical intraepithelial neoplasia grade 3 and cervical cancer in second and subsequent rounds of HPV-based screening are likely to decrease compared to cytology-based screening. In HPV-based screening, the numbers of women with no detectable or minor abnormalities at colposcopy and with screen-detected glandular disease are likely to increase. We have considered how these issues will affect states that have varying implementation of organized cervical screening programs and varying degrees of implementation of HPV testing or vaccination.The development of quality assurance across Europe accompanying these program changes is discussed.
- Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
- Authors: Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM
- Issue date: 2011 Sep
- HPV testing and vaccination in Europe.
- Authors: Leeson SC, Alibegashvili T, Arbyn M, Bergeron C, Carriero C, Mergui JL, Nieminen P, Prendiville W, Redman CW, Rieck GC, Quaas J, Petry KU
- Issue date: 2014 Jan
- Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
- Authors: Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A
- Issue date: 2009 Dec 2
- Human papillomavirus and Papanicolaou tests to screen for cervical cancer.
- Authors: Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J
- Issue date: 2007 Oct 18
- Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.
- Authors: Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, Bogers J, Dachez R, Denton K, Hariri J, Keller T, von Knebel Doeberitz M, Neumann HH, Puig-Tintore LM, Sideri M, Rehm S, Ridder R, PALMS Study Group.
- Issue date: 2013 Oct 16